US 12,128,012 B2
Ketamine treatment for amyotrophic lateral sclerosis
Richard Barohn, Kansas City, MO (US); John A. Stanford, Prairie Village, KS (US); and Matthew Macaluso, Wichita, KS (US)
Assigned to UNIVERSITY OF KANSAS, Lawrence, KS (US)
Appl. No. 17/770,543
Filed by University of Kansas, Lawrence, KS (US)
PCT Filed May 14, 2021, PCT No. PCT/US2021/032519
§ 371(c)(1), (2) Date Apr. 20, 2022,
PCT Pub. No. WO2021/231905, PCT Pub. Date Nov. 18, 2021.
Claims priority of provisional application 63/025,778, filed on May 15, 2020.
Prior Publication US 2023/0066347 A1, Mar. 2, 2023
Int. Cl. A61K 31/135 (2006.01); A61P 25/28 (2006.01)
CPC A61K 31/135 (2013.01) [A61P 25/28 (2018.01)] 20 Claims
 
1. A method of treating the symptoms of symptomatic amyotrophic lateral sclerosis (ALS) in a subject, the method comprising:
providing the subject having been diagnosed with ALS, wherein the subject is in a symptomatic stage of ALS;
providing ketamine;
administering the ketamine to the subject having ALS after onset of muscle wasting or deterioration of muscle function; and
inhibiting muscle wasting or deterioration of muscle function and progression of limb paralysis in the subject having ALS with the ketamine and prolonging survival of the subject.